Metronidazole vaginal gel is a prescription product family used in the clinical management of bacterial vaginosis (BV). U.S. labels distinguish commonly prescribed 0.75% intravaginal gel, including generic products and the Vandazole brand, from a 1.3% single-dose prefilled-applicator presentation marketed as Nuvessa. FDA also approved an ANDA generic referencing Nuvessa 1.3% in March 2024. These products should be identified by their exact reference product, formulation, concentration and applicator system; neither the two concentrations nor a vaginal and skin gel are interchangeable by name.
The distinction is not simply brand versus generic. FDA-approved 0.75% generics relate to the appropriate 0.75% reference product, while the 1.3% generic approved under ANDA 216795 refers specifically to Nuvessa. The Nuvessa label describes a one-time intravaginal 1.3% administration using a single prefilled applicator. A typical 0.75% prescription uses a different labeled multi-day presentation. The 0.75% product guide, Nuvessa brand guide and generic approvals guide explain these three identification questions separately.
This page is the product-choice hub for the vaginal route, not the detailed online-shopping or appointment workflow. A valid prescription is necessary, and a licensed pharmacy should dispense the specifically ordered product with suitable applicators and labeling. Readers whose prescription is already established can use the vaginal-gel pharmacy guide; readers considering skin therapy should use the separate rosacea topical metronidazole overview.
The first decision is which intravaginal prescription family the prescriber selected: 0.75% applicator gel or the distinct 1.3% single-dose presentation. Within each category, brand and approved generic relationships must be confirmed against the specific FDA reference product. Approval of a generic 1.3% gel should not be mistaken for authorization to convert a 0.75% regimen or for proof that a pharmacy currently stocks the generic.
Product concentration, vaginal route, the applicator configuration and the exact instructions must all match the order. The FDA first-generic list identifies Encube Ethicals metronidazole vaginal gel 1.3%, ANDA 216795, approved March 18, 2024; that is a regulatory record, not a live inventory listing. The table separates both generic pathways from brand identities and products for other routes.
| Vaginal product | Concentration | Presentation context | Important check |
|---|---|---|---|
| Generic vaginal metronidazole gel | 0.75% | Prescription intravaginal gel, applicator-based | Exact prescribed product and course |
| Vandazole | 0.75% | Branded vaginal metronidazole gel | Brand status and appropriate substitution |
| Nuvessa | 1.3% | Single-dose prefilled applicator | Different strength and labeled product |
| FDA-approved generic vaginal gel referencing Nuvessa | 1.3% | Single-dose prefilled applicator; ANDA 216795 | Confirm the exact approved product and stock; not equivalent to 0.75% gel |
| Dermal metronidazole gel | May be 0.75% or 1% | Topical rosacea skin medicine | Not for vaginal administration |
| Oral metronidazole | Tablets, capsules or liquid | Systemic treatment by mouth | Not a vaginal gel substitute |
Generic 0.75% vaginal gel is a labeled intravaginal metronidazole formulation, commonly delivered using an applicator and prescribed over a defined course. The CDC lists 0.75% metronidazole vaginal gel among recommended treatments for symptomatic BV. The existence of a guideline regimen does not replace individual evaluation or license patients to adjust the prescription or reuse an old course.
Specific pharmacy packages can differ by manufacturer and applicator contents. A prescription or online listing should identify metronidazole vaginal gel 0.75%, not merely “0.75% metronidazole gel.” The 0.75% vaginal gel guide focuses on that product identity and label details.
Vandazole is a brand name associated with metronidazole 0.75% vaginal gel. The approved branded label documents its vaginal formulation, concentration and applicator context. Generic vaginal metronidazole gel products may be listed separately, with substitution depending on applicable approval information, the exact prescription and pharmacy rules.
A product name does not prove real-time availability. If a prescriber names Vandazole but a pharmacy proposes a generic 0.75% product, ask the pharmacist to confirm its identity and whether the replacement is permitted. Our Vandazole brand guide and generic vaginal gel comparison address that distinction.
Nuvessa 1.3% is a single-dose prefilled intravaginal gel product for BV in females aged 12 and older, with its own label and applicator instructions. In March 2024 FDA approved the first generic referencing this specific product (Encube Ethicals, ANDA 216795). Both branded and approved generic 1.3% products remain distinct from 0.75% vaginal gel; this is not permission to substitute a higher concentration or a one-time regimen for a different prescribed course.
A pharmacy checking a 1.3% prescription can consider exact product identification and permitted brand-to-generic substitution under applicable rules, then separately confirm whether it can actually supply that medicine. The patient should not interpret an FDA approval, DailyMed entry or search-result photograph as proof of inventory or insurance coverage. The Nuvessa product profile concentrates on the branded label, while the generic review explains the related reference product and approval records.
Bacterial vaginosis is associated with an imbalance of vaginal bacteria, but symptoms such as discharge or odor are not exclusive to BV. Other causes of vulvovaginal symptoms may require different testing or management. The CDC describes recommended approaches for symptomatic BV, yet an individual clinician must determine whether the symptoms and examination support that diagnosis.
History of recurrence, pregnancy, allergies and concurrent infections can change the conversation. A remote consultation may be appropriate in some circumstances, while an examination or testing may be needed in others. Use the vaginal prescription pathway for access steps, rather than using product advertisements as a diagnostic test.
Metronidazole is used systemically for trichomoniasis under appropriate clinical guidelines, but vaginal metronidazole gel does not achieve therapeutic levels suitable for treating the infection and is not recommended by CDC for that purpose. Treating suspected trichomoniasis with BV gel may fail to address the infection and delay the necessary diagnosis, appropriate oral treatment and partner-related care.
The distinction illustrates why “metronidazole treats infections” is not specific enough to choose a medicine. If an STI is suspected, appropriate testing and clinician management are important. The trichomoniasis clinical-context page covers that separate indication without positioning vaginal gel as an alternative.
A skin gel intended for rosacea may share the name metronidazole and a concentration number with a vaginal gel, but it is formulated, labeled and packaged for a different route. Skin products are not suitable substitutes for vaginal prescriptions, and intravaginal gels should not be purchased on the assumption that they can treat rosacea. Even the presence of metronidazole in both is not an adequate comparison.
For any pharmacy listing, locate the explicit term vaginal, the concentration and an applicator-based presentation. A listing that only says “metronidazole 0.75% gel” needs clarification. The topical 0.75% guide explains skin gel identity separately.
A valid prescription should make clear the product, vaginal route, concentration and labeled instructions. The pharmacist can confirm whether the prescribed package contains the correct applicators and whether the order names a particular brand. An online pharmacy should require a valid prescription and maintain appropriate U.S. licensure; a description of “fast delivery” is no guarantee of stock or correct dispensing.
If the pharmacy cannot supply Nuvessa, Vandazole or a particular generic, it should coordinate a permitted option with the prescriber rather than making a strength-to-strength conversion on the patient's initiative. The availability guide explains product-level checks, while the online seller checklist focuses on pharmacy legitimacy.
Start with the clinical question: has bacterial vaginosis actually been diagnosed, or are symptoms still being evaluated? If BV is confirmed and the clinician chooses an intravaginal metronidazole product, the next question is which exact presentation was ordered. A prescription for 0.75% gel and a prescription for Nuvessa 1.3% should be interpreted as different product instructions, not two shelf options that a patient can choose between by price or perceived strength.
After that, the pharmacy can confirm the product name, concentration, applicator packaging and lawful dispensing details. If a brand is unavailable, any change belongs to a pharmacist-prescriber discussion. This staged approach keeps medical assessment separate from retail fulfillment and avoids the misleading impression that comparing concentration percentages is a substitute for diagnosis.
A patient who has previously used vaginal metronidazole may recognize the gel and wish to obtain it again when symptoms return. Recurrence does not confirm that the same diagnosis or product is appropriate this time. Clinical reevaluation may be needed to distinguish recurrent BV from another condition, consider pregnancy and assess whether treatment or follow-up should change.
Pharmacy availability should therefore be the last step, not the starting point. A seller advertising a convenient repeat purchase without a valid current prescription cannot establish medical appropriateness. The clinician's plan and the actual product label remain the basis for any refill or new treatment. The page's comparisons should improve prescription literacy, not encourage repeat antibiotic use without assessment.
Vaginal metronidazole labels include contraindications and warnings that require review; lower systemic exposure than an oral tablet should not be interpreted as absence of risk. A prescriber or pharmacist should know about relevant allergies, other medicines, previous reactions and pregnancy status as appropriate. In particular, specific products can have instructions that differ concerning sexual activity, other vaginal products or treatment precautions.
Persistent, recurrent or worsening symptoms merit clinical follow-up rather than repeated unsupervised purchases. Use only the product prescribed, confirm the route and concentration, and seek help for a significant adverse reaction. This product hub is designed to help readers identify medicines, not to replace individualized care.
Certain prescription metronidazole vaginal gels are labeled for bacterial vaginosis. A clinician should confirm the diagnosis and the specific product before treatment.
They are distinct vaginal product concentrations and administration presentations. Nuvessa 1.3% has an FDA-approved generic of its own; neither 1.3% version is a routine substitute for prescribed 0.75% gel.
Vandazole is a branded 0.75% vaginal metronidazole product. The suitability of a generic substitution depends on the exact approved product, prescription and pharmacy rules.
No. A skin formulation is not a vaginal formulation. Matching an ingredient name or percentage does not make the routes interchangeable.
No. Nuvessa is a U.S. prescription medicine and must be dispensed through appropriate pharmacy procedures.
Not necessarily. The products differ in formulation and labeled use; a higher concentration is not a patient-directed reason to switch therapies.
CDC does not recommend metronidazole vaginal gel for trichomoniasis. That infection requires separate clinical evaluation and appropriately selected treatment.
Look for explicit vaginal-route labeling, product concentration, the particular brand or generic identity and applicator-related package details.
Ask the pharmacist about the exact 1.3% brand or approved equivalent and consult the prescriber if a different regimen is needed. Do not convert between 0.75% and 1.3% on your own.
Arrange clinical follow-up rather than starting another course on your own. Persistent or recurrent symptoms may require reevaluation and a different care plan.